OpenAI Nears Astra AI Model Launch With Safety Focus 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Anthropic IPO Marketing Expected to Start in Mid-October 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
REDWOOD CITY, Calif., Feb. 27, 2018 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.
After releasing fourth quarter and full year 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com.
Conference Call Information
When: Thursday, March 8, 2018 at 4:30 p.m. ET
Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)
Conference ID: 7098068
Webcast: http://investors.coherus.com
Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.
About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com.
CONTACT:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
[email protected]
+1 (650) 649-3527
